Maternal Metabolome in Pregnancy and Childhood Asthma or Recurrent Wheeze in the Vitamin D Antenatal Asthma Reduction Trial
Abstract
The in utero environment during pregnancy has important implications for the developing health of the child. We aim to examine the potential impact of maternal metabolome at two different timepoints in pregnancy on offspring respiratory health in early life. In 685 mother-child pairs from the Vitamin D Antenatal Asthma Reduction Trial, we assessed the prospective associations between maternal metabolites at both baseline (10–18 weeks gestation) and third trimester (32–38 weeks gestation) and the risk of child asthma or recurrent wheeze by age three using logistic regression models accounting for confounding factors. Subgroup analyses were performed by child sex. Among 632 metabolites, 19 (3.0%) and 62 (9.8%) from baseline and third trimester, respectively, were associated with the outcome (p-value < 0.05). Coffee-related metabolites in the maternal metabolome appeared to be of particular importance. Caffeine, theophylline, trigonelline, quinate, and 3-hydroxypyridine sulfate were inversely associated with asthma risk at a minimum of one timepoint. Additional observations also highlight the roles of steroid and sphingolipid metabolites. Overall, there was a stronger relationship between the metabolome in later pregnancy and offspring asthma risk. Our results suggest that alterations in prenatal metabolites may act as drivers of the development of offspring asthma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 23, 2021
- Source ID
- 10.3390/metabo11020065
Entities
People
- Bo L Chawes
- Gözde Gürdeniz
- Hans Bisgaard
- Jessica Lasky-Su
- Mengna Huang
- Priyadarshini Kachroo
- Rachel S Kelly
- Scott T Weiss
- Su Chu
Organizations
- National Heart, Lung, and Blood Institute
- National Human Genome Research Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Office of the Director
- United States Department of Defense